Kenvue Inc. (KVUE): Results of Operations and Financial Condition
Kenvue Inc. (KVUE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Kenvue Reports Second Quarter 2026 Results • Delivered Third Consecutive Quarter of Net and Organic Sales 1 Growth • Net Sales Increased 3.0%; Organic Sales Increased 1.6% • Diluted EPS Increased 9% to $0.24; Adjusted Diluted EPS 1 Increased 7% to $0.31 • Results Met or Exceeded
How this was made
The 30-second read
Why it matters
The earnings release provides updated operating performance (sales, EPS, margins) but removes forward-looking guidance due to the pending transaction, increasing reliance on deal-related updates for future expectations.
Market read
Traders get a fresh datapoint on Q2 performance plus an explicit guidance blackout tied to the Kimberly-Clark combination, which can shift near-term positioning.
What to watch
Gross and operating margins declined year over year, with inflation, tariffs, and FX cited as drivers, which could cap upside despite sales growth.
Kenvue Reports Second Quarter 2026 Results
Kenvue delivered its third consecutive quarter of net and organic sales growth, with every segment reporting organic growth and adjusted diluted EPS increasing 7%. Gross profit and operating income margins declined from the prior-year period, while the company withdrew forward-looking guidance because of its pending transaction with Kimberly-Clark.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Net sales growthGAAP | 3.0% | – | increased 3.0% vs the prior year period |
| Organic sales growthnon-GAAP | 1.6% | – | 1.6% |
| Foreign currency benefitother | 1.4% | – | 1.4% |
| Value realizationother | 0.9% | – | – |
| Volume growthother | 0.7% | – | – |
| Gross profit marginGAAP | 58.2% | – | – |
| Adjusted gross profit marginnon-GAAP | 60.2% | – | – |
| Operating income marginGAAP | 17.7% | – | – |
| Adjusted operating income marginnon-GAAP | 22.1% | – | – |
| Interest expense, netGAAP | $90 million | – | – |
| Effective tax rateGAAP | 23.7% | – | – |
| Adjusted effective tax ratenon-GAAP | 22.9% | – | – |
| Diluted earnings per shareGAAP | $0.24 | – | increased 9% |
| Adjusted diluted earnings per sharenon-GAAP | $0.31 | – | increased 7% |
| Net cash flows from operating activitiesGAAP | $1.2 billion | – | – |
| Capital expendituresother | $0.2 billion | – | – |
| Free cash flownon-GAAP | $1.0 billion | – | increased to $1.0 billion vs $0.8 billion in the prior year period |
| Total cash and cash equivalentsGAAP | $1.1 billion | – | – |
| Total debtGAAP | $8.5 billion | – | – |
| Expected pre-tax restructuring expenses and other chargesother | approximately $250 million | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| Self CareFavorable value realization of 1.2% was partially offset by a volume decrease of 0.6%. Return to Organic sales growth in the U.S., strong eCommerce momentum, Allergy activation behind Zyrtec, Digestive Health execution behind Pepcid, and gains in Smoking Cessation and Cough, Cold, & Flu supported performance. | Net sales increased 2.2% vs the prior year period | – | Organic sales growth of 0.6% |
| Skin Health and BeautyFavorable value realization of 2.7% and a volume increase of 1.0% drove growth across every region, largely through Hair Care and Face Care. eCommerce momentum, commercial execution, and innovations including OGX Pro Growth + Peptide and Neutrogena Ultra Sheer Sun contributed. | Net sales increased 5.1% vs the prior year period | – | Organic sales growth of 3.7% |
| Essential HealthA volume increase of 1.9% was partially offset by unfavorable value realization of 0.8%. Wound Care and Baby Care growth, eCommerce momentum, U.S. distribution gains, and targeted innovation activation more than offset an Oral Care decline. | Net sales increased 2.3% vs the prior year period | – | Organic sales growth of 1.1% |
What drove it
- Net sales growth reflected Organic sales growth of 1.6% and a foreign currency benefit of 1.4%.
- Organic sales growth was driven by favorable value realization of 0.9% and volume growth of 0.7%.
- Productivity gains attributable to global supply chain optimization initiatives and favorable value realization partially offset inflation, tariffs, and unfavorable transactional foreign exchange.
- Cost optimization actions, including the 2026 Restructuring Initiative and Our Vue Forward, partially offset increased brand support.
- The effective tax rate reduction largely reflected release of a valuation allowance, favorable jurisdictional mix of earnings, and tax law changes.
- The company received U.S. Food and Drug Administration approval for Tylenol with Naproxen.
Concerns
- Gross profit margin was 58.2% vs 58.9% in the prior-year period, and adjusted gross profit margin was 60.2% vs 60.9%.
- Operating income margin was 17.7% vs 18.0% in the prior-year period, and adjusted operating income margin was 22.1% vs 22.7%.
- Inflation, tariffs, and unfavorable transactional foreign exchange affected both gross profit measures.
- Self Care volume decreased 0.6%.
- Essential Health unfavorable value realization of 0.8% partially offset volume growth, and Oral Care declined.
- The company will not provide forward-looking guidance or host a quarterly conference call due to the pending Kimberly-Clark transaction.
What to watch
- Completion of the Kimberly-Clark transaction, expected to close in the fourth quarter of 2026, subject to foreign regulatory approvals and other customary closing conditions.
- Execution of the 2026 Restructuring Initiative, which is expected to result in pre-tax restructuring expenses and other charges totaling approximately $250 million in fiscal year 2026.
- Whether productivity gains and cost optimization actions offset continuing inflation, tariffs, unfavorable transactional foreign exchange, and higher brand support.
- Availability and commercial rollout of Tylenol with Naproxen, which is expected to be available soon at major U.S. retailers nationwide.
- Sustained U.S. Self Care momentum, including eCommerce, Tylenol consumption trends, and continued performance in Allergy, Digestive Health, Pain, and Cough and Cold.
Balance sheet and cash flow
- Fiscal six months ended June 28, 2026 net cash flows from operating activities were $1.2 billion vs $1.0 billion in the prior year period.
- Capital expenditures were $0.2 billion vs $0.3 billion in the prior year period.
- Free cash flow increased to $1.0 billion vs $0.8 billion in the prior year period.
- Total cash and cash equivalents were $1.1 billion as of June 28, 2026 and December 28, 2025.
- Total debt was $8.5 billion as of June 28, 2026 and December 28, 2025.
Analysis
Kenvue reported a third consecutive quarter of net and organic sales growth. Net sales increased 3.0% versus the prior-year period, comprising Organic sales growth of 1.6% and a foreign currency benefit of 1.4%. Organic growth reflected favorable value realization of 0.9% and volume growth of 0.7%, indicating that both pricing and volume contributed to the reported result.
All three business segments recorded organic sales growth. Skin Health and Beauty was the strongest segment, with net sales increasing 5.1% and Organic sales growth of 3.7%, supported by both favorable value realization of 2.7% and a volume increase of 1.0%. Self Care grew more modestly, with Organic sales growth of 0.6% as 1.2% favorable value realization was partly offset by a 0.6% volume decrease. Essential Health Organic sales increased 1.1%, with volume growth of 1.9% more than offsetting unfavorable value realization of 0.8%.
Profitability declined year over year despite productivity and cost actions. Gross profit margin was 58.2% versus 58.9%, while adjusted gross profit margin was 60.2% versus 60.9%. Operating income margin was 17.7% versus 18.0%, and adjusted operating income margin was 22.1% versus 22.7%. Kenvue cited inflation, tariffs, unfavorable transactional foreign exchange, and higher brand support as pressures, partly offset by supply-chain productivity, the 2026 Restructuring Initiative, and Our Vue Forward.
EPS increased faster than sales. Diluted earnings per share increased 9% to $0.24, and adjusted diluted earnings per share increased 7% to $0.31. The effective tax rate declined to 23.7% from 28.6%, while the adjusted effective tax rate declined to 22.9% from 26.9%, largely due to a valuation-allowance release, favorable jurisdictional mix of earnings, and tax law changes. Interest expense, net, was $90 million versus $94 million.
Cash generation improved during the fiscal six months ended June 28, 2026. Net cash flows from operating activities were $1.2 billion versus $1.0 billion, capital expenditures were $0.2 billion versus $0.3 billion, and free cash flow increased to $1.0 billion versus $0.8 billion. Cash and cash equivalents were $1.1 billion and total debt was $8.5 billion as of both June 28, 2026 and December 28, 2025. Kenvue provided no forward-looking guidance because of its pending transaction with Kimberly-Clark, which is expected to close in the fourth quarter of 2026 subject to stated conditions.
Management, verbatim
We delivered our third consecutive quarter of net and organic sales growth, with broad-based gains across every segment and region.
Kirk Perry, Chief Executive Officer
Our transformation is firmly on track. We remain focused on disciplined execution and continued business improvement while we work toward completing our value-creating combination with Kimberly-Clark in the fourth quarter of this year.
Kirk Perry, Chief Executive Officer
Not in the filing
stated, not guessed- Absolute quarterly net sales were not reported in the supplied filing text.
- Absolute quarterly segment revenue for Self Care, Skin Health and Beauty, and Essential Health was not reported in the supplied filing text.
- GAAP net income was not reported in the supplied filing text.
- GAAP gross profit was not reported in the supplied filing text.
- GAAP operating income was not reported in the supplied filing text.
- Non-GAAP gross profit and non-GAAP operating income amounts were not reported in the supplied filing text.
- Prior-quarter comparisons for reported metrics were not provided.
- Reported year-over-year percentage changes for gross profit margin, adjusted gross profit margin, operating income margin, adjusted operating income margin, interest expense, net, and tax rates were not provided.
- Capital returns, including share repurchases and dividends, were not reported in the supplied filing text.
- Forward-looking financial guidance was not provided; the company stated it will not provide forward-looking guidance due to the pending Kimberly-Clark transaction.
- A previous outlook section was not provided.
AlphaAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
Kenvue filed an SEC 8-K for Q2 2026 results (fiscal quarter ended June 28, 2026) and referenced its planned value-creating combination with Kimberly-Clark expected in Q4 2026.
Ticker impact
Kenvue reported Q2 results with net sales up 3.0% and EPS up, while also stating it will not provide forward guidance due to the Kimberly-Clark combination.
Near-term volatility risk is elevated around deal-related headlines, while the earnings print itself is likely supportive but not decisive without guidance.
The filing provides concrete Q2 financial metrics and explicitly removes forward-looking guidance, which can shift expectations and increase sensitivity to transaction progress.
Market effects
Consumer staples and OTC/pharma-adjacent peers may see read-through on demand resilience and margin sensitivity to inflation/tariffs.
Performance commentary highlights strength in North America, EMEA, and Asia Pacific, which can influence regional consumer staples sentiment.
Foreign currency benefit and tariff/inflation impacts underscore macro sensitivity for multinational consumer brands.
Counterpoint
The guidance blackout reduces the usefulness of the earnings beat, so the market may discount the print and focus on deal execution risk instead.
Key entities
- public_companyKenvue Inc.
Reported Q2 2026 net sales, EPS, margin metrics, and stated it will not provide forward-looking guidance due to the Kimberly-Clark transaction.
- public_companyKimberly-Clark
Counterparty in Kenvue’s pending combination referenced as expected in Q4 2026.
- personKirk Perry
Kenvue CEO quoted on sales growth, operational efficiencies, and transformation progress.
